Daniel Carestio Sells 1,374 Shares of STERIS (NYSE:STE) Stock

STERIS plc (NYSE:STE) CEO Daniel Carestio sold 1,374 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $212.00, for a total transaction of $291,288.00. Following the sale, the chief executive officer owned 63,647 shares of the company’s stock, valued at approximately $13,493,164. This represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Stock Performance

STE stock opened at $212.42 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The stock has a market cap of $20.73 billion, a P/E ratio of 26.79 and a beta of 0.93. The firm has a 50 day simple moving average of $216.83 and a 200 day simple moving average of $238.33. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44.

STERIS (NYSE:STE) last posted its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Research analysts anticipate that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is currently 31.78%.

Institutional Trading of STERIS

A number of institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in STERIS by 2.1% in the first quarter. NewEdge Advisors LLC now owns 8,062 shares of the medical equipment provider’s stock valued at $1,783,000 after acquiring an additional 168 shares during the last quarter. Glenmede Trust Co. NA raised its position in shares of STERIS by 12.2% in the first quarter. Glenmede Trust Co. NA now owns 4,120 shares of the medical equipment provider’s stock valued at $911,000 after purchasing an additional 447 shares during the period. Segall Bryant & Hamill LLC lifted its stake in shares of STERIS by 5.2% in the first quarter. Segall Bryant & Hamill LLC now owns 19,159 shares of the medical equipment provider’s stock worth $4,237,000 after buying an additional 940 shares during the last quarter. Groupe la Francaise boosted its holdings in shares of STERIS by 9.4% during the 1st quarter. Groupe la Francaise now owns 18,514 shares of the medical equipment provider’s stock worth $4,094,000 after buying an additional 1,589 shares during the period. Finally, Western Wealth Management LLC bought a new stake in shares of STERIS during the 1st quarter worth $25,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on STE. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Finally, KeyCorp reduced their target price on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.